Close
Close

Anti-α-N-Cyc-Cer T cell receptor (Vβ8.2), pCDTCR1 (TCR-YC1432)

 Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Vβ8.2 and Vβ7 NKT TCR affinity for CD1d-α-C-GalCer, and some related analogues, is approximately 10-fold lower than that for the NKT TCR-CD1d-α-GalCer interaction. Nevertheless, the crystal structure of the Vβ8.2 NKT TCR-CD1d-α-C-GalCer complex is similar to that of the corresponding NKT TCR-CD1d-α-GalCer complex, although subtle differences at the interface provide a basis for understanding the lower affinity of the NKT TCR-CD1d-α-C-GalCer interaction.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • α-N-Cyc-Cer
  • Epitope
  • α-N-Cyc-Cer
  • Format
  • Non-Modified TCR
  • Allele
  • CD1d
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • Vβ8.2
  • Host Species
  • Human

Target

  • Introduction
  • A series of α-GalCer analogues with modified α-glycosidic linkages were tested for their ability to stimulate splenic NKT cell proliferation and cytokine production. These α-glycoside analogues included α-C-GalCer with a CH2 group in place of the glycosidic oxygen atom; a nonisosteric analogue that has one less CH2 group than α-C-GalCer in the link between the sugar and the sphingolipid (α-1C-GalCer); a compound with a rigid triple bond in the link between the sugar and sphingolipid (α-C-alkyne-GalCer); a variant bearing an ether oxygen atom in the linker (α-C-O-GalCer); and an aminocyclitol variant (α-N-Cyc-Cer). NKT cells respond to a variety of CD1d-restricted glycolipid antigens that are structurally related to the prototypic antigen, α-galactosylceramide (α-GalCer). A modified analogue of α-GalCer with a carbon-based glycosidic linkage (α-C-GalCer) has generated great interest because of its apparent ability to promote prolonged, Th1-biased immune responses.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-α-N-Cyc-Cer T cell receptor (Vβ8.2), pCDTCR1 (TCR-YC1432). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Others

TCR Vector Products

Melanoma

Autoimmune Diseases

Breast cancer

Colorectal cancer

Lung malignancy

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout